An assessment of six placebo-managed scientific trials with one,134 complete individuals concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) ended up linked to a increased normal enhancement within the Ashworth scale for spasticity in a number of sclerosis patients compared with placebo, Though this didn't attain statistical significa

Article Under Review